Panel – Reimagining the Patient Journey for Cell and Gene Therapies: Informing, Engaging and Empowering the Patient Population

Sponsored by: EVERSANA

Seth Gordon, General Manager, EVERSANA™ ENGAGE
Tessa Field, MS, CGC, Sr. Patient Advocacy Lead, Spark Therapeutics
Taren Grom, Co-Founder and Editor, PharmaVOICE (Moderator)

Tuesday - November 23, 2021 / 1:00pm ET
Free Event

Save your spot

Cell and gene therapies (CGTs) hold great life-saving and therapeutic advancement potential, but their complexity requires careful approach–starting with engaging and educating patient communities earlier. While the patient’s voice should be a guiding force throughout the drug development process, it is also critical for those in drug development to participate in educating about these novel treatment approaches to facilitate empowered patient decision making about their own healthcare.

To set the stage for future success, we need to reimagine how patient education and engagement are introduced to the patient journey. How do we ensure all key stakeholders have access to tailored education around a potentially, revolutionary new kind of treatment?

In this 60-minute panel, PharmaVOICE Co-founder and Editor Taren Grom is joined by Seth Gordon, General Manager, EVERSANA™ ENGAGE and Tessa Field, MS, CGC, Sr. Patient Advocacy Lead, Spark Therapeutics to discuss novel ways to incorporate educational pathways along the CGT patient journey.

The panelists will share key insights on:
1. The potential of CGTs for patients, providers, payers, advocacy groups, and caregivers
2. Informing, engaging and empowering patient communities – what it means and why it matters
3. Building a relationship of trust to set the stage for future success
4. Helping patient communities understand the science of CGTs to empower their own decision making

About the Sponsors

EVERSANA is the leading independent provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers and payers.

For more information please visit

Posted in: Gene Therapy, Patients

Comments are closed.